Background-Myocardial infarction (MI) after drug-eluting stent placement has been associated with an unfavorable late prognosis. Although the etiology of periprocedural MI is multifactorial, sidebranch occlusion may be an important contributing factor. We sought to identify the incidence of sidebranch occlusion during zotarolimus-eluting stent (ZES) and paclitaxel-eluting stent (PES) placement and to relate sidebranch occlusion to the occurrence of periprocedural MI. Methods and Results-Angiograms were reviewed from patients randomly assigned to treatment with a ZES (597 patients; 943 sidebranches) or a PES (619 patients; 977 sidebranches). Sidebranch occlusion was defined as Thrombolysis in Myocardial Infarction flow grade 0 or 1. Sidebranch occlusion was correlated with frequency of MI, as assessed by the creatine phosphokinase MB isoenzyme. Sidebranch occlusion occurred less often after the first stent deployment in patients treated with ZES (2.2%) than in patients treated with PES (4.0%; Pϭ0.032). A similar reduction in the frequency of sidebranch occlusion at any point during the procedure was found in patients treated with ZES (2.9% versus 4.8% in PES patients; Pϭ0.042). Multivariable predictors of sidebranch occlusion included baseline sidebranch stenosis, complex lesion morphology, smaller baseline minimal lumen diameters, and the use of a PES.
M yonecrosis after percutaneous coronary intervention (PCI) has been associated with an increased risk of late mortality, 1 particularly in patients with moderately or highly elevated cardiac enzymes after PCI. [2] [3] [4] Although the development of periprocedural myocardial infarction (MI) has been attributed to distal atheroembolism, because of the presence of more severe underlying atherosclerotic disease, 5, 6 periprocedural myonecrosis may also be related to the occlusion of branch vessels during the procedure. 7, 8 Sidebranch occlusion may develop more often in patients treated with coronary stents than balloon angioplasty or atherectomy, because of the mechanical straightening of the vessel and shifting of atherosclerotic plaque into the origin of the sidebranch. 9, 10 Regions of stent overlap may also cause mechanical compromise across the orifice of the branch. Although these effects may be worsened in patients with drug-eluting stents that contain a polymer coating, the fate of sidebranches after drug-eluting stents has not been extensively studied. 11 The Clinical Evaluation of the Medtronic ACE ABT-578 Coated Driver Coronary Stent in De Novo Native Coronary Artery Lesions Study (ENDEAVOR-IV) compared the early and late clinical outcomes of patients treated with the zotarolimus-eluting stent (ZES) and a paclitaxel-eluting stent (PES). The purposes of this analysis were to evaluate sidebranch flow during PCI during placement of these 2 stents and to correlate sidebranch flow with periprocedural myonecrosis and other 30 day clinical outcomes.
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Patient Selection
The ENDEAVOR-IV study compared the early and late clinical outcomes in 1548 patients enrolled at 80 clinical sites (Appendix; available online at http://circinterventions.ahajournals.org) who were assigned to treatment with the Endeavor (Medtronic CardioVascular, Santa Rosa, Calif) ZES (Nϭ773 patients) or the TAXUS Express (Boston Scientific, Natick, Mass) PES (Nϭ775 patients). Informed consent was obtained from all patients enrolled in the study, and the ENDEAVOR-IV protocol was approved by the institutional review boards of the respective institutions. MI was classified as Q-wave or non-Q-wave using the World Health Organization criteria of greater than 2 times normal total creatine phosphokinase (CK) elevation in the presence of isoenzymes (CK-MB). Individual values of CK and CK-MB were collected 2 to 3 times before hospital discharge or for recurrent ischemia and were compared with reference levels. This post hoc analysis included the 1216 patients in whom at least 1 sidebranch Ͼ1 mm in diameter was identified by the angiographic core laboratory within the target lesion or its 5-mm proximal or distal margin.
Angiographic Analysis
Standard image acquisition was performed at the clinical sites using 2 or more angiographic projections of the stenosis and intracoronary nitroglycerin to provide maximum coronary vasodilation. Angiograms were then forwarded to the Brigham and Women's Hospital Angiographic Core Laboratory (Boston, Mass) for review by observers who were blinded to the treatment assignment. All procedural angiograms were reviewed using standard morphologic criteria. 12 Lesion length was defined as the axial extent of the lesion that contained a shoulder-to-shoulder lumen reduction by 20% or more. Coronary dissections were assessed using the National Heart, Lung, and Blood Institute criteria. 13 The 3 largest sidebranches Ͼ1 mm in diameter and originating within the stent or its 5 mm proximal or distal margins were included in the analysis. The size of the sidebranch was characterized as small (extending to one third of the myocardial distribution), medium (extending to two thirds of the myocardial distribution), and large (extending to the full extent of the myocardial distribution). Sidebranch occlusion was defined as a reduction in Thrombolysis in Myocardial Infarction (TIMI) flow to grade 0 or 1 14 during the procedure (Figures 1 and 2 ). Reduced sidebranch flow included those branches that showed a reduction in TIMI flow by 1 or more grades during the procedure, and sidebranch narrowing was defined as the progression of the sidebranch percent diameter stenosis from Ͻ70% to Ͼ70% during the procedure. The sidebranch flow, occurrence of no reflow, abrupt closure, dissection, and distal emboliza- tion were assessed at baseline, after balloon predilation, after initial stent deployment, following last stent deployment, and after final balloon inflation.
Using the contrast filled injection catheter as the calibration source, quantitative angiographic analysis was performed using a validated automated edge detection algorithm (Medis CMS, Leiden, The Netherlands). 15 Selected images for analysis were identified using angiographic projections that demonstrated the stenosis in an unforeshortened view, minimized the degree of vessel overlap, and displayed the stenosis in its "sharpest and tightest" view. A 5-mm segment of reference diameter proximal and distal to the stenosis was used to calculate the average reference vessel diameter at baseline, after stent implantation, and at follow-up. Sidebranches and other anatomic landmarks were used to identify and maintain the consistency of the measurement length during the follow-up period. Minimal lumen diameters (MLDs) were measured at these same time points within the stent (in-stent analysis), within the 5-mm proximal and distal edges of the stent, and within the segment between the proximal and distal reference vessel (in-segment analysis).
Statistical Analysis
Analysis was performed on a per-lesion basis. Categorical data are expressed as rates or proportions, and continuous variables are expressed as meanϮSD. Binary variables were compared using Fisher exact test and continuous variables were compared using the Student t test. Multivariate analysis was performed using logistic regression analysis. All analyses were performed using SAS version 8.0 (SAS Institute, Cary, NC). A 2-sided P value Յ0.05 was considered significant.
Results
Study Population
A total of 597 patients (943 sidebranches) were treated with ZES, and 619 patients (977 sidebranches) were treated with PES. There were no differences in the baseline clinical characteristics in patients treated with ZES or PES ( Table 1) . Multivessel coronary artery disease was present in more than 40% of patients. Aspirin was given before the procedure in 96.4% of patients, and clopidogrel was given before the procedure in 64.1% of patients. Glyoprotein IIb-IIIa inhibitors were used before the procedure in 27.8% of patients. 
Popma et al Sidebranch Occlusion After DESAngiographic Findings
There were no differences in the baseline angiographic findings in the patient treated with ZES or PES ( Table 2) . Additional adverse characteristics included lesion eccentricity (41.7%), tortuosity (11.3%), ostial location (2.2%), and thrombus (1.2%) of patients. There were no differences in the quantitative angiographic finding at baseline or after stent placement. The frequency of postprocedural thrombus (0.1%) and National Heart, Lung, and Blood Institute dissection grade ՆB (1.2%) was not different in the 2 groups. Postprocedural TIMI flow grade 3 was present in 99.2% of patients in both groups. Implanted stent diameters were 2.50 (21.7%), 2.75 (2.9%), 3.0 (42.5%), 3.5 (32.9%), and 4.0 mm (0.1%).
The maximum balloon inflation pressure was 13.7Ϯ2.7 atmospheres with the stent deployment and 15.4Ϯ3.4 atmospheres with postdeployment stent dilation. There were more stents used in patients treated with the TAXUS stent (1.13Ϯ0.39) than in patients treated with the Endeavor stent (08Ϯ0.34; Pϭ0.027), although the total stent length was similar in the 2 groups (21.83Ϯ8.41 versus 21.53Ϯ8.10, respectively). The average sidebranch diameter was 1.52Ϯ0.37 mm (Table 3 ). There were no differences in the length or distribution of the sidebranch in patients treated with ZES or PES. Sidebranch occlusion occurred less often after the first stent deployment in patients treated with the ZES (2.2%) than in patients treated with the PES (4.0%; Pϭ0.032). Sidebranch occlusion at any point during the procedure was noted in 70 patients (73 sidebranches), including 25 (2.9%) patients treated with ZES and 45 (4.8%) patients treated with PES (Pϭ0.042). One patient in each group had occluded sidebranches at the end of the procedure but patent sidebranches at follow-up. Multivariable predictors of sidebranch occlusion included the baseline sidebranch stenosis, complex lesion morphology, smaller baseline minimal lumen diameters, and the use of a PES (Table 4 ). There were no significant differences in the frequency of glycoprotein IIb-IIIa inhibitor use in patents with (30%) and without (27.7%) sidebranch occlusion.
There were also no differences in the occurrence of no reflow, TIMI flow Ͻ3, National Heart, Lung, and Blood Institute dissections ՆB, or distal embolization within the parent vessel during the procedure in patients treated with ZES or PES.
Clinical Outcomes
Early (30-day) and late clinical events in patients with and without sidebranch occlusions are found in (Table 5) . Periprocedural MI occurred within 30 days of the procedure in 14 patients (2.3%) treated with PES and 6 patients (1.0%) treated with ZES (Pϭ0.113), primarily due to more frequent occurrence of World Health Organization-defined non-Qwave MI in patients treated with PES (2.1% versus 0.7% in patients treated with ZES; Pϭ0.048). Of the 20 patients with MI within 30 days of the procedure, 30% had evidence of sidebranch occlusion at some point during the stent procedure (ZES, 2; PES, 4). The magnitude of CK-MB elevations was higher in patients treated with PES ( Figure 3 ). Protocoldefined stent thrombosis occurred in 4 patients, but none of these patients developed sidebranch occlusion during the stent procedure.
Sidebranch occlusion was associated with a significant increase in total CK-MB compared with patients who did not develop sidebranch occlusion during the procedure ( Figure  4 ). Multivariable predictors of CK-MB elevations more than 3 times normal are found in (Table 6 ). Major adverse cardiac events at 360 days were significantly higher in patients with sidebranch occlusion, although there were no differences in late mortality (Table 5) .
Discussion
In this post hoc analysis of 1216 patients who were randomly assigned to treatment with a ZES or a PES who were found to have at least 1 sidebranch greater than 1 mm in diameter within its origin in the stented segment or its 5-mm margins, use of the ZES was associated with less sidebranch occlusion than use of the PES. Sidebranch occlusion was an important predictor of periprocedural MI, and independent correlates of sidebranch occlusion included lesion complexity, severity of the baseline stenosis, and use of a PES. Of patients in this series with a protocol-defined MI within 30 days of the procedure, 30% were found to have sidebranch occlusion at 
Periprocedural Myonecrosis and Clinical Outcomes
Myocardial necrosis after PCI is a recognized complication of the procedure and had been attributed to large sidebranch occlusion, 6 distal embolization, 16 loss of collaterals, coronary dissection, and reduced flow due to microvascular obstruction. 7, 8, 17 A consensus statement from the European Society of Cardiology, American College of Cardiology, American Heart Association, and World Heart Foundation has established that an elevation of 3 times the 99th percentile of the upper normal limit of cardiac biomarkers is diagnostic of a periprocedural MI. 17 Although early analyses suggested that the magnitude of myocardial necrosis was an important determinant of late mortality, 1 additional studies suggested that the degree of underlying atherosclerosis was an important confounding factor as well as the fact that the relationship between myocardial necrosis and late mortality was strongest when the infarction was large (Ͼ5 to 10 times normal). 3, 4, 18 
Periprocedural MI and Sidebranch Occlusion With Coronary Stents
Coronary stenting has improved clinical outcomes of patients undergoing PCI by scaffolding coronary arteries and preventing early and late arterial recoil. Coronary stenting may also substantially alter the vessel conformation, and compromise the origin of sidebranches due to either plaque shifting or change in the angle of the sidebranch origin. In addition, coronary stenting may also cause microvascular obstruction due to embolization. 19 Another well recognized cause of periprocedural MI is the compromise of large sidebranches after stenting, 20 although the fate of smaller branches after stent placement has been less well studied. In a series of 153 patients undergoing Palmaz-Schatz stent placement, of the 60 sidebranches without ostial disease after conventional angioplasty, 57 (95%) remained patent immediately after stenting. 9 In contrast, 6 of 27 sidebranches with a 50% or greater ostial stenosis occluded during the procedure. 9 Similar results were found in patients treated with the Gianturco-Roubin coil stent design. 10 In another study of 151 patients undergoing direct stent placement (nϭ88) or conventional stenting after predilatation (nϭ63), sidebranch occlusion was observed in 18.2% of patient undergoing direct stenting and 24% of those undergoing conventional stent placement. 21 In that series, most sidebranch occlusions were seen in patients with type D sidebranch morphology involving both the parent vessel and the sidebranch (PϽ0.001) and in cases with sidebranch ostial diameter stenosis Ͼ50%. 21 Another series assessed sidebranch occlusion after direct intracoronary stenting in 86 patients with 111 sidebranches. 22 Sidebranches with Ͼ50% stenosis that take off within or just beyond the diseased portion of the lesion (unfavorable morphology) were the most powerful morphological predictor of sidebranch occlusion (odds ratio, 8.0; 95% CI, 1.5 to 40.8; Pϭ0.007). 22 It is not known whether the use of drug-eluting stents increases the risk of sidebranch occlusion due to the polymer coating, drug elution, or both. A detailed angiographic analysis of 238 patients treated with the CYPHER sirolimuseluting stent and Bx Velocity bare metal stent (both Cordis Corporation, Warren, NJ) evaluated the fate of sidebranches after stent implantation. 11 One or more sidebranches were identified in 128 patients, including 63 patients in the sirolimus-eluting stent group with 118 sidebranches and 65 patients in the bare metal stent group with 124 sidebranches. 11 There were no differences in the rate of sidebranch occlusion in patients treated with the sirolimus-eluting stent (10%) versus bare metal stent (7%). 11 Spontaneous recanalization of the occluded branches was observed in 92% branches in the sirolimus-eluting stent group and in 67% branches in the bare metal stent group. 11 In this study, smaller (1.4-mm) sidebranch compromise did occur in some patients after stent placement, and up to 30% of periprocedural MIs were associated with sidebranch occlusion. More frequent sidebranch occlusion was found in patients treated with PES than in those treated with ZES, and this likely accounted for the differences in periprocedural MI observed in this study.
Factors Influencing Side Branch Occlusion
Prior studies have suggested that significant atherosclerotic disease in the sidebranch was the major determinant of sidebranch occlusion during the procedure. In this study, both lesion complexity and the baseline stenosis severity, as assessed by the baseline minimal lumen diameters, were independent determinants of sidebranch occlusion. This is likely due to the degree of atherosclerosis that is shifted to the origin of the sidebranch after stent placement. Another independent predictor of sidebranch occlusion in this study was the use of the PES. The 3.0-mm diameter TAXUS Express2 stent is composed of 316L stainless steel that has a strut thickness of 132 m and has a polymer thickness of 16 m, yielding a total thickness of 148 m. In comparison, the 3.0-mm diameter Endeavor stent is composed of cobalt chromium with a strut thickness of 91 m and a phosphorylcholine and zotarolimus thickness of 5.3 m, yielding a total thickness of 96.3 m. One potential explanation is that the greater thickness of the TAXUS stent obstructed the origin of the branch vessel and restricted flow into the distal vessel. Another potential explanation is that there may be enhanced platelet aggregation and embolization into the sidebranch of the TAXUS stent that does not occur with the Endeavor stent due to the thromboresistance of the phosphorylcholine coating. A less likely explanation is that there may be paclitaxelinduced spasm or polymer webbing or clumping that would predispose to platelet aggregation. Additional studies will be required to determine the precise mechanism of benefit of the ZES on the preservation of sidebranch patency during the procedure. 
Limitations
This is a retrospective posthoc analysis that was driven by the observation that non-Q-wave MIs occurred more often in PES than ZES treated patients. The analysis was limited to the largest 3 sidebranches within the vessel and may underestimate the effect of sidebranch occlusion at other sites. No specific instructions were given to the clinical sites to record angiographic evidence of sidebranch occlusion, and some transient episodes of sidebranch occlusion may have been missed. Troponin measurements may be a more sensitive detector of myonecrosis after PCI, 23 but were not used as part of this study. As a result, the true incidence of MI may be underestimated.
Conclusions
This study showed that sidebranch occlusion was an important factor contributing to postprocedural myonecrosis after ZES and PES placement and that treatment with a ZES was associated with less frequent sidebranch occlusion than treatment with a PES. Although the precise mechanisms have yet to be determined, the reduced sidebranch occlusion associated with the use of the ZES likely resulted in lower rates of non-Q-wave MI within 30 days of the procedure. Newer drug-eluting stent designs may have important effects on the preservation of sidebranch flow during the procedure, and these modifications may improve the safety of this procedure in patients with complex coronary artery disease.
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